
Shafiq Rehman
Contact Info
Office Hours
- Today
- -
Shafiq Rehman
About Shafiq Rehman
Mr Rehman has dedicated his professional life to Ophthalmology since 1994. His first mentors noticed his natural ability to meet the demands of Ophthalmic surgery and Shafiq sailed through higher surgical training gaining his CCST in 2002 and was invited to take up a substantive NHS consultant post at Calderdale & Huddersfield NHS Trust in the same year. Over the next ten years, Shafiq proved himself to be a great pioneer of breakthrough treatments, he has distinguished himself on numerous occasions by spearheading major ophthalmic developments and as such has successfully notched up several noteworthy ‘firsts’ in the Yorkshire region and beyond.
Never one to rest on former achievements, he continues to devote much time and energy towards further innovation with particular emphasis on helping to encourage the adoption of new ideas wherever they have been clearly proven to help improve the lives of his patients. He works tirelessly to identify innovative new developments in macular degeneration, cataract surgery and vision correction technology, bringing major advancements in eye care from around the world.
His incredible drive and commitment to helping develop the very best service possible with state-of-the-art technology have been recognised by Optegra who appointed him as lead clinician for their Cataract & Refractive Surgery services across the seven UK Optegra Eye Hospitals. His passion and desire to provide excellent eye care to every one of his patients continue to remain undimmed despite the quarter-century of experience behind him. He is delighted to be able to offer Visian ICL implantation as part of his full range of vision correction treatment options.
Select Your Region
Latin America
References
1. Packer M. The Implantable Collamer Lens with a central port: review of the literature. Clin Ophthalmol. 2018;12:2427-2438.
2. Martínez-Plaza E, López-Miguel A, López-De La Rosa A, et al. Effect of the EVO+ Visian Phakic Implantable Collamer Lens on Visual Performance and Quality of Vision and Life, Am J Ophthalmol 2021;226: 117-125.
3. Packer M. Evaluation of the EVO/EVO+ Sphere and Toric Visian ICL: Six Month Results from the United States Food and Drug Administration Clinical Trial. Clin Ophthalmol. 2022;16:1541-53.
4. Parkhurst GD. A prospective comparison of phakic collamer lenses and wavefront-optimized laser-assisted in situ keratomileusis for correction of myopia. Clin Ophthalmol. 2016;10:1209-1215.
5. Zhang H, Deng Y, Ma K, Yin H, Tang J. Analysis on the changes of objective indicators of dry eye after implantable collamer lens (ICL) implantation surgery. Graefes Arch Clin Exp Ophthalmol. 2024 Jul;262(7):2321-2328.
6. Albo C, Nasser T, Szynkarski DT, Nguyen N, Mueller B, Libfraind L, Parkhurst G. A Comprehensive Retrospective Analysis of EVO/EVO+ Implantable Collamer Lens: Evaluating Refractive Outcomes in the Largest Single Center Study of ICL Patients in the United States. Clin Ophthalmol. 2024 Jan 9;18:69-78.
Important Safety Information
The ICL is designed for the correction/reduction of myopia in patients, 21 to 60 years of age, ranging from -0.5 D to -20.0 D with or without astigmatism up to 6.0 D and the correction/reduction of hyperopia in patients, from 21 to 45 years of age, with hyperopia ranging from +0.5 D to +16.0 D with or without astigmatism up to 6.0 D. In order to be sure that your surgeon will use a ICL with the most adequate power for your eye, your nearsightedness, farsightedness and astigmatism should be stable for at least a year before undergoing eye surgery. ICL surgery may improve your vision without eyeglasses or contact lenses. ICL surgery does not eliminate the need for reading glasses, even if you have never worn them before. ICL represents an alternative to other refractive surgeries including, laser assisted in situ keratomileusis (LASIK), photorefractive keratectomy (PRK), incisional surgeries, or other means to correct your vision such as contact lenses and eye glasses. Implantation of an ICL is a surgical procedure, and as such, carries potentially serious risks. The following represent potential complications/adverse reactions reported in conjunction with refractive surgery in general: additional surgeries, cataract formation, loss of best corrected vision, raised pressure inside the eye, loss of cells on the innermost surface of the cornea, conjunctival irritation, acute corneal swelling, persistent corneal swelling, endophthalmitis (total eye infection), significant glare and/or halos around lights, hyphaema (blood in the eye), hypopyon (pus in the eye), eye infection, ICL dislocation, macular oedema, non-reactive pupil, pupillary block glaucoma, severe inflammation of the eye, iritis, uveitis, vitreous loss and corneal transplant. Before considering ICL surgery you should have a complete eye examination and talk with your eye care professional about ICL surgery, especially the potential benefits, risks, and complications. You should discuss the time needed for healing after surgery.